1 / 4

Global Cyclosporine drugs Market Trends, Size, Competitive Analysis and Forecast 2020-2026

The global cyclosporine drug market is estimated to grow at a CAGR of around 5% during the forecast period. A cyclosporine drug is a drug which used as medication during the organ transplant such as liver, kidney, heart.

mansi3210
Télécharger la présentation

Global Cyclosporine drugs Market Trends, Size, Competitive Analysis and Forecast 2020-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Orion Market Research Global Cyclosporine drugs Market, Size, Share, Analysis Report & Forecast to 2026 Request https://www.omrglobal.com/request-sample/cyclosporine-drugs-market a Free Sample of our Global Cyclosporine drugs Market: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

  2. The global cyclosporine drugs market is anticipated to showcase considerable growth during the forecast period (2020-2026). The new product launches with rising FDA approvals are a factor contributing to the growth of the global cyclosporine drugs market. Cyclosporine drug is an immunosuppressant class of drugs that is extracted from Tolypocladium fungus which prevents side effects on the immune system such as encephalomyelitis, graft diseases, allograft rejection, delayed hypersensitivity and experimental allergy. In addition, the cyclosporine drug is used in the treatment of a broad spectrum of diseases such as dry eye syndrome, rheumatoid arthritis, and psoriasis. Neoral and Sandimmune are the available drug formulations for the oral route, and Restasis is used for ocular delivery of cyclosporine. A https://www.omrglobal.com/industry-reports/cyclosporine-drugs-market full Report of Global Cyclosporine drugs Market is Available at: AbbVie Inc., Allergan PLC, Apotex Inc., Eon Labs, Mayne Pharma Group Ltd. McKesson Medical- Surgical Inc., Novartis Inc., Santen Inc., Sun Pharmaceuticals, Teva Pharmaceuticals, and so on are the key players operating in the global cyclosporine drugs market. These players are actively involved in adopting different growth strategies such as mergers and acquisitions, partnerships, collaboration, and strategic agreements among others to remain competitive in the market place. New product launches and investment in the R&D is the key strategy adopted by the players of the global cyclosporine drugs market to sustain their marketplace. For instance, in March 2019, Breath Therapeutics Inc. had announced the launch of a Ph3 trial for the inhaled liposomal cyclosporine A therapy. In August 2018, Sun Pharmaceutical Industries Ltd. had received US FDA approval for CEQUA (cyclosporine ophthalmic solution) 0.09%. CEQUA is an aqueous solution used to increase tear production in patients suffering from keratoconjunctivitis sicca (dry eye). CEQUA provides the highest FDA-approved concentration of cyclosporine A (CsA) and is based on nanomicellar technology. The innovative nanomicellar formulation used in CEQUA allows the CsA molecule to overcome the solubility challenges involved in the treatment of the dry eyes by penetrating the eye’s aqueous layer and preventing the release of the active lipophilic molecule before the actual penetration. In May 2018, Teva Canada Ltd, a subsidiary of Teva Pharmaceutical Industries Ltd., had launched Teva-Cyclosporine ophthalmic emulsion, 0.05% w/v, a Health Canada approved twice- daily eye drop solution and the first generic version of Restasis (cyclosporine) in Canada. Cyclosporine ophthalmic emulsion is produced for the treatment of moderate to moderately severe aqueous deficient dry eye syndrome having ocular staining, reduction in tear production, and fluctuating visual symptoms. Request https://www.omrglobal.com/request-sample/cyclosporine-drugs-market a Free Sample of our Global Cyclosporine drugs Market: Cyclosporine Drugs Market Segmentation By Indication

  3.      Rheumatoid Arthritis Psoriasis Transplant Rejection Prophylaxis Dry Eye Autoimmune Myasthenia Gravis Other By Route of Administration   Oral Parenteral Cyclosporine Drugs market – Segment by Region North America   The US Canada Europe       Germany UK France Spain Italy Rest of Europe Asia-Pacific     China Japan India Rest of Asia-Pacific Rest of the World   Latin America Middle East & Africa Company Profiles AbbVie Inc. Allergan PLC Apotex, Inc. Mayne Pharma Group Ltd.

  4. Mckesson Medical Surgical Inc. Novartis AG Otsuka Pharmaceutical Co. Ltd. Regenerx Biopharmaceuticals, Inc. Santen Pharmaceuticals Co. Ltd. Sun Pharmaceuticals Industries, Ltd. Takeda Pharmaceutical Co. Ltd. Teva Pharmaceuticals Industries, Ltd. United Biotech Pvt. Ltd. For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report- customization/cyclosporine-drugs-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research- based services. For More Information, Visit Orion Market Research Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 7803040404

More Related